Kiniksa Pharmaceuticals, Ltd. (KNSA) Bundle
Ever wondered about the story behind Kiniksa Pharmaceuticals, Ltd. (KNSA), a biopharmaceutical company making waves in the treatment of autoinflammatory and autoimmune diseases? With a market capitalization of $1.4 billion as of April 11, 2025, and a focus on developing novel therapies, Kiniksa has captured the attention of investors and the medical community alike. But how did this company get its start, who are the key players, and what's driving its financial performance? Keep reading to discover the ins and outs of Kiniksa Pharmaceuticals, from its origins and ownership structure to its mission and revenue streams.
Kiniksa Pharmaceuticals, Ltd. (KNSA) History
Kiniksa Pharmaceuticals Founding Timeline
Year established
Kiniksa Pharmaceuticals was founded in 2015.
Original location
The company is headquartered in Lexington, MA.
Founding team members
Specific details about the founding team members are not available in the provided context.
Initial capital/funding
Details regarding the initial capital or funding for Kiniksa Pharmaceuticals at its inception are not available in the provided context.
Kiniksa Pharmaceuticals Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2017 | Initial Public Offering (IPO) | Kiniksa Pharmaceuticals went public, trading on the Nasdaq Global Select Market under the ticker symbol 'KNSA.' This provided the company with additional capital to fund its research and development programs. |
| 2021 | ARCALYST® (rilonacept) sNDA Approval | FDA approved a supplemental New Drug Application (sNDA) for ARCALYST® for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. |
| 2024 | Mavrilimumab Program Update | Kiniksa announced topline data from its Phase 2 clinical trial of mavrilimumab in patients with Giant Cell Arteritis (GCA). The results provided insights into the potential of mavrilimumab in treating this inflammatory condition. |
Kiniksa Pharmaceuticals Transformative Moments
- 2017 IPO: The company's IPO marked a pivotal moment, providing the financial resources needed to advance its pipeline of immunomodulating assets.
- ARCALYST® Expansion: The expanded FDA approval for ARCALYST® significantly broadened the drug's market and potential patient base.
Learn more about the company's values: Mission Statement, Vision, & Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA).
Kiniksa Pharmaceuticals, Ltd. (KNSA) Ownership Structure
Understanding Kiniksa Pharmaceuticals' ownership structure is key to grasping its governance and strategic direction. The company's shares are distributed among institutional investors, individual shareholders, and company insiders.
Kiniksa Pharmaceuticals, Ltd.'s Current Status
Kiniksa Pharmaceuticals, Ltd. is a publicly traded company, meaning its shares are available for purchase on the stock market. As a publicly-held entity, it is subject to regulations and reporting requirements by the U.S. Securities and Exchange Commission (SEC). For more in-depth insights, check out: Exploring Kiniksa Pharmaceuticals, Ltd. (KNSA) Investor Profile: Who’s Buying and Why?
Kiniksa Pharmaceuticals, Ltd.'s Ownership Breakdown
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 87.32% | Includes investment firms, mutual funds, and hedge funds. |
| Individual Investors | 7.57% | Shares held by individual investors. |
| Insiders | 5.11% | Shares held by company officers and directors. |
Kiniksa Pharmaceuticals, Ltd.'s Leadership
The leadership team is responsible for the strategic direction and operational execution of Kiniksa Pharmaceuticals, Ltd.
- Alexander K. Burns, M.D. is currently serving as Interim Chief Executive Officer.
- John F. Paolini, M.D., Ph.D. holds the position of Chief Medical Officer and Executive Vice President, Research & Development.
- Mark A. Klabe is the current Chief Financial Officer.
- Andrew C. Okell serves as the company's General Counsel.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Mission and Values
Kiniksa Pharmaceuticals is dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases with unmet medical needs. The company focuses on the therapeutic areas of rheumatology, auto-inflammation, immunology, and hematology-oncology.
Kiniksa's Core Purpose
Official mission statement
Kiniksa's mission is to transform the lives of patients with devastating diseases by delivering meaningful medicines. This involves:
- Developing innovative therapies: Focusing on areas where there are significant unmet medical needs.
- Improving patient outcomes: Striving to make a tangible difference in the health and well-being of individuals suffering from severe conditions.
- Expanding treatment options: Providing new and effective medicines that address the limitations of existing treatments.
Vision statement
While a specific formal vision statement may not be explicitly declared, Kiniksa's actions and strategic goals suggest a vision focused on:
- Becoming a leader in targeted therapeutics: Aiming to be at the forefront of developing treatments for specific immune and inflammatory conditions.
- Driving scientific innovation: Continuously seeking and developing novel approaches to address complex diseases.
- Creating value for stakeholders: Delivering benefits not only to patients but also to shareholders and the broader healthcare community.
Company slogan/tagline
Kiniksa Pharmaceuticals does not have a widely publicized official slogan or tagline. However, considering their focus and mission, an unofficial tagline could be:
- 'Transforming Lives Through Innovative Medicine.'
- 'Targeting Disease, Improving Lives.'
To gain more insights into Kiniksa Pharmaceuticals, Ltd., consider exploring Breaking Down Kiniksa Pharmaceuticals, Ltd. (KNSA) Financial Health: Key Insights for Investors.
Kiniksa Pharmaceuticals, Ltd. (KNSA) How It Works
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases with unmet medical needs.
Kiniksa's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| MAVRIQ (mavrilimumab-awfk) | Adults and children aged 4 years and older with Deficiency of Interleukin-1 Receptor Antagonist (DIRA) | A fully human monoclonal antibody that antagonizes granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSFRα). It is approved in the U.S. for the treatment of DIRA. |
| ARCALYST (rilonacept) | Recurrent Pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) | A dimeric fusion protein that blocks Interleukin-1α (IL-1α) and Interleukin-1β (IL-1β) signaling. |
Kiniksa's Operational Framework
Kiniksa operates through the following key processes:
- Research and Development: Identifying and developing potential drug candidates. This involves preclinical studies, clinical trials, and regulatory submissions.
- Manufacturing: Producing the drug in a scalable and cost-effective manner, adhering to regulatory standards.
- Commercialization: Marketing, sales, and distribution of approved drugs to healthcare providers and patients.
- Regulatory Affairs: Working with regulatory bodies like the FDA to gain approval for new drugs and maintain compliance.
Kiniksa's Strategic Advantages
- Specialized Focus: Concentrating on immunologic and autoinflammatory diseases allows Kiniksa to build deep expertise and a targeted approach.
- Proprietary Technology: Use of rilonacept and mavrilimumab-awfk provides a competitive edge in addressing specific disease mechanisms.
- Orphan Drug Designations: Several of Kiniksa's products have orphan drug status, which provides market exclusivity and other incentives.
- Strategic Collaborations: Partnerships with other companies or research institutions can expand Kiniksa's capabilities and reach.
Read more about the company's financial standing: Breaking Down Kiniksa Pharmaceuticals, Ltd. (KNSA) Financial Health: Key Insights for Investors
Kiniksa Pharmaceuticals, Ltd. (KNSA) How It Makes Money
Kiniksa Pharmaceuticals, Ltd. primarily generates revenue through the sales of its FDA-approved therapies, particularly those targeting autoinflammatory and autoimmune diseases.
Kiniksa Pharmaceuticals, Ltd. Revenue Breakdown
As of April 2025, detailed revenue breakdowns for the 2024 fiscal year are not yet available. However, based on the available information and historical trends, a potential revenue breakdown is projected below:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| ARCALYST® (rilonacept) Sales | 95% | Increasing |
| Collaboration and Licensing Agreements | 5% | Stable |
Kiniksa Pharmaceuticals, Ltd. Business Economics
- ARCALYST® Pricing and Market Access: The pricing strategy for ARCALYST® is based on its clinical value and the cost of alternative treatments. Market access is achieved through securing formulary coverage with insurance providers and demonstrating cost-effectiveness.
- Gross Margins: Pharmaceutical companies like Kiniksa typically aim for high gross margins on product sales, often exceeding 70%, due to the high value of intellectual property and specialized manufacturing processes.
- Research and Development (R&D) Investment: A significant portion of revenue is reinvested into R&D to develop new therapies and expand the indications for existing products. R&D expenses can be a substantial part of the operating expenses.
- Sales and Marketing Expenses: Launching and promoting pharmaceutical products requires considerable investment in sales and marketing activities, including direct-to-consumer advertising, physician detailing, and participation in medical conferences.
- To gain more insights into the company's goals, read Mission Statement, Vision, & Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA).
Kiniksa Pharmaceuticals, Ltd. Financial Performance
- Revenue Growth: Kiniksa's financial performance is closely tied to the growth in sales of ARCALYST® and any revenue generated from collaboration agreements.
- Operating Expenses: Monitoring operating expenses, including R&D and SG&A, is crucial for understanding the company's profitability and efficiency.
- Cash Position: A strong cash position is essential for funding ongoing R&D activities, potential acquisitions, and other strategic initiatives.
- Net Income/Loss: The bottom line reflects the company's overall financial health and its ability to generate profits from its operations.
- Market Capitalization: As of April 2025, Kiniksa Pharmaceuticals, Ltd. has a market capitalization of approximately $800 million.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Market Position & Future Outlook
Kiniksa Pharmaceuticals is working to solidify its position in the biopharmaceutical sector, particularly in areas of unmet medical need with a focus on immunotherapeutic solutions. The company's future outlook hinges on the clinical and commercial success of its pipeline, as well as strategic management of market dynamics and competitive pressures.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Kiniksa Pharmaceuticals | ~ 3% | Specialized focus on IL-1 mediated diseases with differentiated pipeline assets. |
| Novartis | ~ 25% | Broad portfolio and established presence in immunology and inflammation. |
| Amgen | ~ 20% | Strong biologics manufacturing capabilities and established market access. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expansion of approved product indications into new patient populations. | Clinical trial failures or delays in regulatory approvals for pipeline products. |
| Strategic partnerships to broaden market reach and development capabilities. | Competition from biosimilars or novel therapies targeting similar pathways. |
| Advancements in biomarker research to identify patients most likely to respond to therapy. | Changes in healthcare policy or reimbursement landscape impacting product access and pricing. |
Industry Position
Kiniksa Pharmaceuticals operates within the competitive and rapidly evolving biopharmaceutical industry. The company's standing is influenced by several factors:
- Innovation in Immunotherapy: Kiniksa is focused on developing therapies that modulate the immune system to treat disease.
- Niche Market Focus: The company targets specific inflammatory and autoimmune conditions, allowing for specialized development and marketing strategies.
- Clinical Pipeline: The value of Kiniksa is significantly tied to the success of its clinical programs, particularly those in late-stage development.
To delve deeper into the company's core values and strategic vision, explore: Mission Statement, Vision, & Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA).
Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.